Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma

Table 2 Univariate and multivariate analyses of prognostic factors for overall survival of hepatitis B virus-associated intrahepatic cholangiocarcinoma patients included in this study

Variable	n	Univariate analysis			Multivariateanalyses
		1-yr	5-yr	P value	HR	95%CI	P value
Gender				0.205	NA	NA	NA
Female	19	66%	23%
Male	66	58%	10%
Age				0.769	NA	NA	NA
≤ 60	59	64%	13%
> 60	26	50%	12%
Capsule formation				0.522	NA	NA	NA
Yes	32	55%	10%
No	53	63%	14%
Cirrhosis				0.002	1.981	1.197-3.278	0.008
Yes	48	56%	0%
No	37	65%	27%
Child-Pugh class				0.257	NA	NA	NA
A	76	61%	14%
B	9	18%	0%
AFP (ng/mL)				0.342	NA	NA	NA
≤ 20	48	51%	11%
> 20	37	72%	15%
CA19-9 (U/mL)				0.342	NA	NA	NA
≤ 37	55	66%	14%
> 37	30	50%	10%
Gross type				0.402	NA	NA	NA
MF	63	61%	13%
PI + IG	22	56%	11%
Differentiation				0.119	NA	NA	NA
Well or Moderate	63	64%	16%
Poor	22	50%	0%
Tumor number				< 0.001	2.653	1.562-4.508	< 0.001
Single	60	69%	17%
Multiple	25	38%	0%
Tumor size				0.006	NA	NA	NA
< 5 cm	43	70%	21%
≥ 5 cm	42	49%	5%
LN metastasis				0.005	NA	NA	NA
Yes	11	31%	0%
No	74	64%	14%
Vascular invasion				0.013	NA	NA	NA
Yes	11	24%	0%
No	74	64%	14%
TNM classification				< 0.001	NA	NA	NA
Stage I or II	61	66%	17%
Stage III or IV	24	43%	0%
Width of resection margin				0.274	NA	NA	NA
< 1 cm	37	69%	17%
≥ 1 cm	48	53%	9%
Surgical procedure				0.962	NA	NA	NA
Major hepatectomy	40	61%	13%
Minor hepatectomy	45	59%	12%

AFP: Alpha-fetoprotein; CA19-9: Carbohydrate antigen 19-9; MF: Mass-forming; PI: Periductal infiltrating; IG: Intraductal growth; TNM: Tumor-node-metastasis; NA: Not available; HR: Hazard ratio; LN: Lymph node.